The company
Neurogene Inc.
NGNE · Nasdaq
NGNE stood above a rising 150-day average in 24 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 23.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $2.3M
- Officials’ trades on record
- 0
- Institutions holding
- 112 (+17)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 24 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Christine Mikail CvijicPresident and CFO | sold | 4,200at $36.13 | 7 Jul 2026filed 7 Jul 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 600at $36.02 | 6 Jul 2026filed 7 Jul 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 2,531at $34.58 | 2 Jul 2026filed 2 Jul 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 1,530at $35.23 | 2 Jul 2026filed 2 Jul 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 739at $34.06 | 1 Jul 2026filed 2 Jul 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 4,800at $30.07 | 6 May 2026filed 8 May 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 4,800at $32.44 | 6 May 2026filed 8 May 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 2,558at $21.62 | 26 Mar 2026filed 30 Mar 2026 |
| Rachel McMinnChief Executive Officer | sold | 3,352at $22.07 | 26 Mar 2026filed 30 Mar 2026 |
| Julie JordanChief Medical Officer | sold | 828at $21.89 | 26 Mar 2026filed 30 Mar 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 2,387at $20.42 | 13 Mar 2026filed 17 Mar 2026 |
| Christine Mikail CvijicPresident and CFO | sold | 1,395at $21.25 | 13 Mar 2026filed 17 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 2026 | 1,717,127$54.0M | 00.0% |
| Casdin Capital, LLCadded · filed 14 Aug 2026 | 1,545,361$48.6M | +125,000+8.8% |
| Redmile Group, LLCreduced · filed 14 Aug 2026 | 1,412,199$44.4M | -47,400−3.2% |
| RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026 | 1,362,456$42.8M | 00.0% |
| EcoR1 Capital, LLCunchanged · filed 14 Aug 2026 | 1,271,342$40.0M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 1,057,983$33.3M | +52,913+5.3% |
| BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 2026 | 991,691$31.2M | 00.0% |
| Balyasny Asset Management L.P.added · filed 14 Aug 2026 | 818,706$25.7M | +100,317+14.0% |
| Trails Edge Capital Partners, LPreduced · filed 14 Aug 2026 | 714,885$22.5M | -67,902−8.7% |
| TORONTO DOMINION BANKunchanged · filed 14 Aug 2026 | 681,337$21.4M | 00.0% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.